Japanese researchers found that Akt-mTOR pathway-related proteins were activated in DFSP and that the Akt-mTOR pathway is a potential therapeutic target in imatinib-resistant DFSP or FS-DFSP (81). Here, AKT1 is linked to dermatofibrosarcoma protuberans.